Literature DB >> 11929127

From A to Z on CpG.

Arthur M Krieg1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11929127     DOI： 10.1016/s1471-4906(01)02150-0

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


× No keyword cloud information.
  10 in total

Review 1.  Role of Toll-like receptors in pathogen recognition.

Authors:  S Janssens; R Beyaert
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

2.  Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.

Authors:  Amani Makkouk; Vijaya B Joshi; Amaraporn Wongrakpanich; Caitlin D Lemke; Brett P Gross; Aliasger K Salem; George J Weiner
Journal:  AAPS J       Date:  2014-10-18       Impact factor: 4.009

3.  Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits.

Authors:  Henrieta Scholtzova; Eileen Do; Shleshma Dhakal; Yanjie Sun; Shan Liu; Pankaj D Mehta; Thomas Wisniewski
Journal:  J Neurosci       Date:  2017-01-25       Impact factor: 6.167

4.  Role of Toll-like receptors in activation of porcine alveolar macrophages by porcine reproductive and respiratory syndrome virus.

Authors:  Laura C Miller; Kelly M Lager; Marcus E Kehrli
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

5.  Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis.

Authors:  Banani Banerjee; Kevin J Kelly; Jordan N Fink; James D Henderson; Naveen K Bansal; Viswanath P Kurup
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 6.  Injection site reactions after subcutaneous oligonucleotide therapy.

Authors:  Leonie van Meer; Matthijs Moerland; Jolie Gallagher; Martijn B A van Doorn; Errol P Prens; Adam F Cohen; Robert Rissmann; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2016-05-31       Impact factor: 4.335

7.  Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations.

Authors:  Mohamed A EL-Malky; Saeed A Al-Harthi; Raafat T Mohamed; Mohamed A EL Bali; Niveen S Saudy
Journal:  Parasitol Res       Date:  2014-04-13       Impact factor: 2.289

8.  Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection.

Authors:  Linda J Berry; Danica K Hickey; Kathryn A Skelding; Shisan Bao; Amanda M Rendina; Philip M Hansbro; Christine M Gockel; Kenneth W Beagley
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Interferon-alpha/beta receptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide 2006.

Authors:  Atsushi Kato; Toshiki Homma; Jonathan Batchelor; Noriko Hashimoto; Shosuke Imai; Hiroshi Wakiguchi; Hirohisa Saito; Kenji Matsumoto
Journal:  BMC Immunol       Date:  2003-07-30       Impact factor: 3.615

10.  Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey (Saimiri Boliviensis Boliviensis).

Authors:  Pramod N Nehete; Lawrence E Williams; Sriram Chitta; Bharti P Nehete; Akash G Patel; Margish D Ramani; Thomas Wisniewski; Henrieta Scholtzova
Journal:  Front Aging Neurosci       Date:  2020-03-03       Impact factor: 5.750
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.